Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2021 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)

REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
September 08, 2021 07:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
September 02, 2021 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
August 26, 2021 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody™ technology to create new immune-stimulating antibody conjugates (ISACs)Innovent...
August 12, 2021 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

– BDC-1001 Phase 1/2 trial in HER2-expressing solid tumors on track for data update in 2H 2021– – Announced R&D collaboration with Genmab to develop multiple bispecific ISACs for treatment of...
June 04, 2021 09:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody™ ISAC BDC-1001 as of January 29th cutoff dateMonotherapy dose expansion and anti-PD-1...
June 02, 2021 08:00 ET | Source: Bolt Biotherapeutics, Inc.

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

Media Release Collaboration to discover and evaluate novel product concepts based on the combination of Genmab’s antibodies and bispecific antibody technologies with Bolt’s proprietary...
May 13, 2021 16:05 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights

– Strong cash position of $302.9 million as of March 31, 2021 expected to deliver key value-creating milestones and fund operations into 2023 – – Upsized IPO in February 2021 raised $264.5 million in...
April 10, 2021 08:30 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

REDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
April 08, 2021 07:00 ET | Source: Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...